These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 32966321)

  • 1. Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19.
    Tahseen S; Khanzada FM; Rizvi AH; Qadir M; Ghazal A; Baloch AQ; Mustafa T
    PLoS One; 2020; 15(9):e0239328. PubMed ID: 32966321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand.
    Prommi A; Wongjarit K; Petsong S; Somsukpiroh U; Faksri K; Kawkitinarong K; Payungporn S; Rotcheewaphan S
    Microbiol Spectr; 2024 Mar; 12(3):e0346223. PubMed ID: 38323824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.
    Pillay S; Steingart KR; Davies GR; Chaplin M; De Vos M; Schumacher SG; Warren R; Theron G
    Cochrane Database Syst Rev; 2022 May; 5(5):CD014841. PubMed ID: 35583175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
    Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S
    BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of drug resistance by Sanger sequencing of Mycobacterium tuberculosis complex strains isolated from multidrug resistant tuberculosis suspect patients in Ethiopia.
    Mesfin EA; Merker M; Beyene D; Tesfaye A; Shuaib YA; Addise D; Tessema B; Niemann S
    PLoS One; 2022; 17(8):e0271508. PubMed ID: 35930613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data.
    Dean AS; Zignol M; Cabibbe AM; Falzon D; Glaziou P; Cirillo DM; Köser CU; Gonzalez-Angulo LY; Tosas-Auget O; Ismail N; Tahseen S; Ama MCG; Skrahina A; Alikhanova N; Kamal SMM; Floyd K
    PLoS Med; 2020 Jan; 17(1):e1003008. PubMed ID: 31961877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrazinamide resistance in rifampicin discordant tuberculosis.
    Mvelase NR; Singh R; Swe Swe-Han K; Mlisana KP
    PLoS One; 2022; 17(9):e0274688. PubMed ID: 36129921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High isoniazid resistance rates in rifampicin susceptible Mycobacterium tuberculosis pulmonary isolates from Pakistan.
    Fasih N; Rafiq Y; Jabeen K; Hasan R
    PLoS One; 2012; 7(11):e50551. PubMed ID: 23226311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiological profile of patients with rifampicin-resistant tuberculosis: an analysis of the Uganda National Tuberculosis Reference Laboratory Surveillance Data, 2014-2018.
    Bahizi G; Majwala RK; Kisaka S; Nyombi A; Musisi K; Kwesiga B; Bulage L; Ario AR; Turyahabwe S
    Antimicrob Resist Infect Control; 2021 May; 10(1):76. PubMed ID: 33964986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs.
    Imperiale BR; Di Giulio ÁB; Adrián Cataldi A; Morcillo NS
    J Antibiot (Tokyo); 2014 Nov; 67(11):749-54. PubMed ID: 24894185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalences of levofloxacin resistance and
    Ng KKM; Yip PCW; Leung PKL
    Hong Kong Med J; 2021 Dec; 27(6):421-427. PubMed ID: 34949730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.
    Cornejo Garcia JG; Alarcón Guizado VA; Mendoza Ticona A; Alarcon E; Heldal E; Moore DAJ
    PLoS One; 2018; 13(12):e0206658. PubMed ID: 30513085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tuberculosis Laboratory Surveillance Network (TuLSA) study group. The first step for national tuberculosis laboratory surveillance: Ankara, 2011].
    Sezen F; Albayrak N; Özkara Ş; Karagöz A; Alp A; Duyar Ağca F; İnan Süer A; Müderris T; Ceyhan İ; Durmaz R; Ertek M;
    Mikrobiyol Bul; 2015 Apr; 49(2):143-55. PubMed ID: 26167815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa.
    Pitso L; Potgieter S; Van der Spoel van Dijk A
    S Afr Med J; 2019 Aug; 109(9):659-664. PubMed ID: 31635590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance mutations and heteroresistance detected using the GenoType MTBDRplus assay and their implication for treatment outcomes in patients from Mumbai, India.
    Tolani MP; D'souza DT; Mistry NF
    BMC Infect Dis; 2012 Jan; 12():9. PubMed ID: 22260344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COMPLIANCE OF INITIALLY PRESCRIBED ANTI-TUBERCULOSIS TREATMENT REGIMENS WITH COMPLETE DRUG SUSCEPTIBILITY TEST RESULTS AND ITS ASSOCIATION WITH TREATMENT OUTCOMES IN GEORGIA (2015-2020).
    Solomonia N; Vacharadze K
    Georgian Med News; 2020 Dec; (309):72-81. PubMed ID: 33526733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of line probe assay-based molecular testing on individualized treatment in patients with rifampicin-resistant tuberculosis: data from the prospective INNOVA4TB cohort study in Ukraine.
    Dudnyk A; Hempel M; Lytvyniuk O; Liudkevych H; Matsera V; Nikitchenko T; Blyzniuk S; Molina-Moya B; Preyer R; Domínguez J
    Ther Adv Respir Dis; 2024; 18():17534666241249841. PubMed ID: 38817020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Whole-genome sequencing in drug susceptibility testing of Mycobacterium tuberculosis in routine practice in Lyon, France.
    Genestet C; Hodille E; Berland JL; Ginevra C; Bryant JE; Ader F; Lina G; Dumitrescu O;
    Int J Antimicrob Agents; 2020 Apr; 55(4):105912. PubMed ID: 31991222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing.
    Valvatne H; Syre H; Kross M; Stavrum R; Ti T; Phyu S; Grewal HM
    J Antimicrob Chemother; 2009 Oct; 64(4):694-701. PubMed ID: 19710078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning.
    Dixit A; Freschi L; Vargas R; Gröschel MI; Nakhoul M; Tahseen S; Alam SMM; Kamal SMM; Skrahina A; Basilio RP; Lim DR; Ismail N; Farhat MR
    BMJ Glob Health; 2024 Mar; 9(3):. PubMed ID: 38548342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.